Average Co-Inventor Count = 5.58
ph-index = 15
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Boehringer Ingelheim Pharmaceuticals, Inc. (35 from 276 patents)
2. Boehringer Ingelheim International Gmbh (18 from 1,535 patents)
3. Morphic Therapeutic, Inc. (4 from 15 patents)
4. Petra Pharma Corporation (4 from 4 patents)
5. Hibercell, Inc. (3 from 10 patents)
64 patents:
1. 12459942 - Inhibiting (α-v)(β-6) integrin
2. 12030862 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
3. 11919902 - Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
4. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
5. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
6. 11739087 - Inhibiting (α-v)(β-6) integrin
7. 11667651 - Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
8. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
9. 11584763 - Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
10. 11370773 - Inhibiting human integrin (alpha-4) (beta-7)
11. 11104661 - Inhibiting human integrin (α-4) (β-7)
12. 8957063 - Amine and ether compounds which modulate the CB2 receptor
13. 8889670 - Heterocyclic compounds which modulate the CB2 receptor
14. 8846936 - Sulfonyl compounds which modulate the CB2 receptor
15. 8829034 - Compounds which modulate the CB2 receptor